Latest news
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - simplywall.stsimplywall.st · Sat, 01 Aug 2026 19:22:36 GMTNovo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9% - BioSpaceBioSpace · Fri, 31 Jul 2026 15:27:37 GMTNovo Nordisk’s mAb for MACE risk reduction fails in Phase III trial - Clinical Trials ArenaClinical Trials Arena · Fri, 31 Jul 2026 15:22:14 GMTNovo Nordisk Shares Drop After Drug Candidate Fails in Trial - WSJWSJ · Fri, 31 Jul 2026 14:40:00 GMTNovo Nordisk’s anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial - SRN NewsSRN News · Fri, 31 Jul 2026 12:41:25 GMTNovo drug trial fail deals setback to bid to expand beyond obesity - ReutersReuters · Fri, 31 Jul 2026 07:00:00 GMTNovo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - CNBCCNBC · Fri, 31 Jul 2026 07:00:00 GMTNovo Nordisk drops as anti-inflammatory drug fails in late-stage trial - Seeking AlphaSeeking Alpha · Fri, 31 Jul 2026 07:00:00 GMT